HDHajira Dambha-Miller

Hajira Dambha-Miller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hajira Dambha-Miller has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    When Markets Shape AI Mental Health Self-Management Tools: Consequences for Serious Mental Illness

    by Lucy Smith, Yousef Yousef, Piotr Wasilewski, Hajira Dambha-Miller

    AI-enabled self-management health tools are increasingly promoted within health care policy as part of digital self-management models for mental health care. However, development is concentrated on scalable, low-intensity interventions for common conditions, such as anxiety and depression, rather than on populations with the greatest clinical need, such as those with serious mental illness (SMI). This includes schizophrenia-spectrum and bipolar disorders, which remain comparatively underserved, despite experiencing a disproportionate burden of morbidity and service use. However, the clinical features of SMI—comprising fluctuating symptoms, multimorbidity, and elevated risk—may limit the suitability of low-intensity AI-driven self-management tools designed for mild-to-moderate conditions. In this Viewpoint, we argue that the scarcity of AI-enabled self-management tools for SMI reflects a structural feature of current innovation systems rather than one of technical infeasibility alone. Market incentives, regulatory pathways, and fragmented research pipelines favor low-risk, high-volume populations, thereby limiting development for clinically complex groups. Addressing this unevenness is essential and will require upstream intervention, including targeted public funding, improved data infrastructure, and administrative frameworks that support safe innovation in high-risk populations. Embedding equity for SMI as a primary design requirement will be necessary to ensure that AI-driven mental health tools do not reinforce current inequalities.


  • Open Access

    Frequency, Clinical Characteristics, Anatomical Distribution, and Outcomes of Embolic Complications of Cardiac Myxoma in Contemporary Cohorts: Protocol for a Systematic Review and Meta-Analysis

    by Arun Dahil, Callum Hill, Cameron Pinn, David Hardisty, Piotr Wasilewski, Matthew Turner, Michaela Scheuermann-Freestone

    Background: Cardiac myxomas (CMs) are the commonest benign primary cardiac tumors, most frequently originating from the left atrium and occasionally from the right atrium. Despite being histologically benign, CMs can cause myriad serious embolic complications, including stroke, acute coronary syndrome, limb ischemia, and visceral infarction. While previous studies have explored risk factors for embolization, there is a lack of papers comprehensively summarizing the frequency, anatomical distribution, clinical patterns, and management of CM-related embolization. Objective: This review aims to provide a comprehensive synthesis of embolic complications associated with CMs, highlighting patterns, management strategies, and gaps in the current literature. Methods: A systematic review will be conducted in accordance with the PRISMA-P (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols) guidelines. MEDLINE, Embase, Scopus, CINAHL, the Cochrane Library, and PubMed will be searched for studies reporting embolic complications in patients with histologically or radiologically confirmed CMs. Eligible study designs include large case series, cohort studies, and registries. Six reviewers will independently perform title and abstract and full-text screening in pairs across 3 screening groups, with disagreements resolved through discussion and senior reviewer adjudication where necessary. Data will be extracted by 3 reviewers, with the extracted data independently verified for accuracy. Discrepancies will be resolved through discussion or third-party adjudication. Risk of bias will be assessed using the Joanna Briggs Institute tools. Results: The review will summarize reported frequencies and anatomical distribution of embolic events, clinical presentations, associations with tumor characteristics, and management strategies. Title and abstract screening were completed in early April 2026, and full-text screening commenced in late April 2026. Data extraction and synthesis were completed in May 2026. We anticipate publication of the findings in September 2026. Conclusions: This review aims to provide a comprehensive synthesis of embolic complications associated with CMs, highlighting patterns, management strategies, and gaps in the current literature. The findings aim to improve clinical recognition, inform clinical management, and guide future research.

  • Open Access

    When Markets Shape AI Mental Health Self-Management Tools: Implications for Serious Mental Illness (Preprint)

    by Lucy Smith, Yousef Yousef, Piotr Wasilewski, Hajira Dambha-Miller

    UNSTRUCTURED Artificial intelligence (AI)-enabled health tools are increasingly promoted within healthcare policy as part of digital self-management models for mental health care. However, development is concentrated on scalable, low-intensity interventions for common conditions such as anxiety and depression, rather than on populations with the greatest clinical need, such as those with serious mental illness (SMI). This includes schizophrenia-spectrum and bipolar disorders, for example, which remain comparatively underserved, although experiencing a disproportionate burden of morbidity and service use. The clinical features of SMI -comprising fluctuating symptoms, multimorbidity, and elevated risk limit the suitability of low-intensity AI-driven self-management tools designed for mild-to-moderate conditions. This Viewpoint argues that the scarcity of AI-enabled self-management tools for SMI reflects a common issue in current innovation systems rather than one of technical infeasibility alone. Market incentives, regulatory pathways, and fragmented research pipelines favour low-risk, high-volume populations, while limiting development for clinically complex groups. Addressing this unevenness is essential and will require upstream intervention, including targeted public funding, improved data infrastructure, and administrative frameworks that support safe innovation in high-risk populations. Embedding equity for SMI as a primary design requirement will be necessary to ensure that AI-driven mental health tools do not reinforce current inequalities.